Lifeboat Foundation

While there are ways to alleviate some symptoms, there is currently no way to prevent or cure Parkinson’s disease, so the prospect of a one-off treatment that completely eliminates it is certainly an exciting one. While such a therapy remains a while off, scientists have demonstrated an exciting proof of concept in mice, whereby inhibiting a single gene as a one-time treatment eradicated the disease entirely, and kept it at bay for the remainder of their lives.

The research was carried out at the University of California, San Diego (UCSD), and centers on a protein called PTB, which plays a role in which genes are switch on and off in a cell. The team was experimenting with techniques whereby the gene that encodes for PTB is switched off so researchers can determine the flow-on effects of a reduction in the that protein on other cell types, and found peculiar results when working with connective tissue cells called fibroblasts.

In one experiment, the team created a cell line that was permanently lacking PTB, and after a couple of weeks found that there was only a small amount of fibroblasts remaining in the dish, which was brimming with neurons instead. Building on this, the team was able to use a single treatment to inhibit the activity of PTB in mice, which reprogrammed support cells in the brain called astrocytes into neurons that produce the neurotransmitter dopamine.

Rich experiences—from play to the arts and relationships—fundamentally shape a young child’s development.

By Rishi Sriram

Approach could lead to new ways to treat epilepsy, depression, and Alzheimer’s disease.

The article is providing an answer to the following questions that are relevant to the study of intelligence:

What is “understanding”?

How can we tell whether a system has it or not? https://bit.ly/3fynqYu

Continue reading “Consciousness – An obstacle to the understanding of intelligence” »

Xiang-Dong Fu, PhD, has never been more excited about something in his entire career. He has long studied the basic biology of RNA, a genetic cousin of DNA, and the proteins that bind it. But a single discovery has launched Fu into a completely new field: neuroscience.

For decades, Fu and his team at University of California San Diego School of Medicine studied a protein called PTB, which is well known for binding RNA and influencing which genes are turned “on” or “off” in a cell. To study the role of a protein like PTB, scientists often manipulate cells to reduce the amount of that protein, and then watch to see what happens.

But then he noticed something odd after a couple of weeks — there were very few fibroblasts left. Almost the whole dish was instead filled with neurons.

Continue reading “One-Time Treatment Generates New Neurons, Eliminates Parkinson’s Disease in Mice” »

A trove of DNA sequences from 141,456 people — and counting — offers researchers an unparalleled look at genetic variation across the general population^1,2. The resource has been helping researchers to identify variants that contribute to autism since it was released online about four years ago^3,4.

The genomes of autistic people harbor hundreds of potentially harmful mutations. But to firmly connect a specific variant to the condition, researchers need to see if it is common among typical people — a sign that that variant may actually be benign.

In 2014, researchers debuted one of the first tools to probe the prevalence of a mutation in the general population. Known as the Exome Aggregation Consortium (ExAC), it contained 60,000 sequences of exomes — the protein-coding regions of the genome⁵.

Complex behavioral phenotyping techniques are becoming more prevalent in the field of behavioral neuroscience, and thus methods for manipulating neuronal activity must be adapted to fit into such paradigms. Here, we present a head-mounted, magnetically activated device for wireless optogenetic manipulation that is compact, simple to construct, and suitable for use in group-living mice in an enriched semi-natural arena over several days. Using this device, we demonstrate that repeated activation of oxytocin neurons in male mice can have different effects on pro-social and agonistic behaviors, depending on the social context. Our findings support the social salience hypothesis of oxytocin and emphasize the importance of the environment in the study of social neuromodulators. Our wireless optogenetic device can be easily adapted for use in a variety of behavioral paradigms, which are normally hindered by tethered light delivery or a limited environment.

How does the neural activity evoked by visual stimuli support visual awareness? In this paper we report on an individual with a rare type of neural degeneration as a window into the neural responses underlying visual awareness. When presented with stimuli containing faces and target words—regardless of whether the patient was aware of their presence—the neurophysiological responses were indistinguishable. These data support the possibility that extensive visual processing, up to and including activation of identity, can occur without resulting in visual awareness of the stimuli.

Visual awareness is thought to result from integration of low- and high-level processing; instances of integration failure provide a crucial window into the cognitive and neural bases of awareness. We present neurophysiological evidence of complex cognitive processing in the absence of awareness, raising questions about the conditions necessary for visual awareness. We describe an individual with a neurodegenerative disease who exhibits impaired visual awareness for the digits 2 to 9, and stimuli presented in close proximity to these digits, due to perceptual distortion. We identified robust event-related potential responses indicating 1) face detection with the component and 2) task-dependent target-word detection with the P3b component, despite no awareness of the presence of faces or target words.

The world’s largest genetic study into chronic fatigue syndrome is to be launched in the UK after receiving £3.2m of funding from the Medical Research Council and National Institute for Health Research.

The research aims to shine a light on the debilitating long-term condition, about which little is known, by collecting DNA samples from 20,000 people who have CFS, also known as myalgic encephalomyelitis (ME).

CFS is believed to affect about 250,000 people in the UK and has been estimated to cost the economy billions of pounds each year. Individuals experience exhaustion that is not helped by rest, with one in four so severely affected they are unable to leave the house and, frequently, unable to leave their bed. Other symptoms include, pain, mental fogginess, light and noise sensitivities, as well as trouble with memory and sleep. No effective treatment exists.